Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis

Keyphrases

• Control Subjects 28%
• Diabetes Inpatients 14%
• Early Signs 100%
• Gastrointestinal 42%
• Gastrointestinal Factors 14%
• Gastrointestinal System 14%
• Glucagon 14%
• Glucose Disposal 28%
• Glucose Dysmetabolism 100%
• Glucose Infusion 14%
• Glucose Metabolism 14%
• Glucose-dependent Insulinotropic Polypeptide 14%
• Glucose-tolerant 14%
• Healthy Individuals 14%
• Increased Vulnerability 14%
• Incretin Effect 100%
• Incretin Hormones 28%
• Insulin Secretion 14%
• Intolerant 14%
• Moderate-to-severe Psoriasis 14%
• Non-diabetic 100%
• Normal Glucose Tolerance 14%
• Oral Glucose Tolerance Test 14%
• Postprandial Insulin 14%
• Potentiation 14%
• Pre-diabetes (pre-DM) 14%
• Psoriasis 100%
• Type 2 Diabetes Mellitus (T2DM) 28%
• Type 2 Diabetes Risk 14%

Medicine and Dentistry

• Gastric Inhibitory Polypeptide 12%
• Gastrointestinal System 12%
• Glucagon 12%
• Glucose Infusion 12%
• Glucose Metabolism 25%
• Gut 25%
• Incretin 100%
• Insulin Release 12%
• Maturity Onset Diabetes of the Young 37%
• Oral Glucose Tolerance Test 12%
• Psoriasis 100%
• Secretion (Process) 12%

Biochemistry, Genetics and Molecular Biology

• Gastric Inhibitory Polypeptide 16%
• Glucagon 16%
• Glucose Metabolism 33%
• Incretin 100%
• Insulin Release 16%
• Secretion (Process) 16%